Skip to main content

ASCPT 2025 Annual Meeting Main banner

Oncology (ONC)

Oncology (ONC)

Type here to filter the list

PI-026 - A STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF THREE NAPAROFENIB (LXH254) FORMULATIONS IN HEALTHY SUBJECTS

Favorite
PT-005 - GRIN2 IS A POWERFUL TOOL TO IDENTIFY GENOMIC HOT-SPOT LOCI AND ENABLES MULTI-OMICS INTEGRATION.

Favorite
PT-006 - PHARMACOKINETIC DRUG-DRUG INTERACTION POTENTIAL OF ORAL ANTICANCER DRUGS.

Favorite
PII-026 - AN INTEGRATED PK/PD MODELING FRAMEWORK OF NONCLINICAL EFFICACY AND CLINICAL HEMATOLOGICAL SAFETY TO INFORM DOSE SELECTION OF ATRI TUVUSERTIB IN COMBINATION WITH NIRAPARIB IN PATIENTS WITH PARPI-RESISTANT OVARIAN CANCER

Favorite
PII-027 - CHARACTERIZING NETUPITANT'S FUNCTION AS AN NADK2 INHIBITOR: IMPACT ON CELL VIABILITY AND METABOLISM.

Favorite
PII-028 - CLONAL HEMATOPOIESIS AS A PRECISION MEDICINE BIOMARKER FOR PATIENTS WITH CANCER

Favorite
PII-029 - EFFECT OF RENAL FUNCTION IMPAIRMENT ON THE PHARMACOKINETICS (PK) OF PARSACLISIB, A SELECTIVE INHIBITOR OF PI3Kδ

Favorite
PII-031 - INFORMATIVE CENSORING BIAS IN DOSE-RESPONSE ANALYSIS OF PROGRESSION-FREE SURVIVAL OF ANTICANCER DRUGS

Favorite
PII-032 - MOVING TOWARD "FIT-FOR-PURPOSE" QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODELING IN DRUG DEVELOPMENT: CASE EXAMPLES IN ONCOLOGY.

Favorite
PII-033 - NO EFFECT OF IMMUNOGENICITY ON THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF THE NOVEL OLIGONUCLEOTIDE TELOMERASE INHIBITOR IMETELSTAT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

Favorite
PII-034 - OPTIMIZING DOSE SELECTION FOR CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY IN THE TREATMENT OF PATIENTS WITH CANCER : A SYSTEMATIC REVIEW OF MECHANISTIC IN SILICO MODELS.

Favorite
PII-035 - PHARMACOKINETICS OF AMG 193 (A SMALL MOLECULE MTA-COOPERATIVE PRMT5 INHIBITOR) AFTER SINGLE AND MULTIPLE DOSING IN THE FASTED AND FED IN STATE PATIENTS WITH MTAP DELETED TUMORS

Favorite
PII-036 - PRECLINICAL TO CLINICAL TRANSLATION OF ADVERSE EVENTS FOR SMALL MOLECULE ONCOLOGY DRUGS

Favorite
PII-037 - REAL-WORLD CHARACTERIZATION OF DRUG-DRUG INTERACTIONS AMONG PATIENTS WITH ONCOGENE-DRIVEN NON-SMALL CELL LUNG CANCER USING TYROSINE KINASE INHIBITORS

Favorite
PII-038 - STRATEGIC CONSIDERATIONS FOR TUMOR DYNAMICS MODELING IN EARLY DEVELOPMENT: LEARNINGS FROM AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE

Favorite
PII-039 - THE EFFECT OF CARBAMAZEPINE ON THE PHARMACOKINETICS (PK) OF VEPDEGESTRANT, A PROTEOLYSIS TARGETING CHIMERA (PROTAC) ESTROGEN RECEPTOR (ER) DEGRADER IN HEALTHY ADULTS.

Favorite
PII-040 - THE IMPACT OF MILD, MODERATE AND SEVERE LIVER DYSFUNCTION ON THE PHARMACOKINETIC DISPOSITION OF MEZIGDOMIDE

Favorite
LB-004 - COUPLING BIOMARKER KNOWLEDGE WITH THE STRENGTHS OF PHARMACOMETRICS AND MACHINE LEARNING FOR INDIVIDUAL PROGNOSIS IN ONCOLOGY: A PRECISION MEDICINE FRAMEWORK FOR HEALTH CARE PROVIDERS

Favorite
LB-005 - TALAZOPARIB FORMULATION BRIDGING IN CANCER PATIENTS-CHALLENGES AND THE CRITICAL ROLE OF MIDD IN APPROVAL DESPITE FAILED BIOEQUIVALENCE

Favorite
PI-027 - ASSESSING BASELINE AND LONGITUDINAL CIRCULATING TUMOR DNA WITH PROGRESSION FREE SURVIVAL (PFS) IN BRAF V600E MUTANT (BRAFM) METASTATIC COLORECTAL CANCER (MCRC).

Favorite
PI-028 - CLINICAL PHARMACOKINETICS AND BIOMARKER ANALYSES OF RC88, A NEW MESOTHELIN-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS

Favorite
PI-029 - EFFECT OF HEPATIC FUNCTION IMPAIRMENT ON THE PHARMACOKINETICS (PK) OF PARSACLISIB, A SELECTIVE INHIBITOR OF PI3Kδ

Favorite
PI-030 - EFFECT OF VALEMETOSTAT ON THE PHARMACOKINETICS OF MIDAZOLAM AND DIGOXIN (CYP3A AND P-GP SUBSTRATES): A PHASE 1 DRUG-DRUG INTERACTION STUDY IN PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN LYMPHOMA.

Favorite
PI-032 - MODEL INFORMED DOSE OPTIMIZATION OF BOTENSILIMAB ALONE AND IN COMBINATION WITH BALSTILIMAB IN PATIENTS WITH SOLID TUMORS

Favorite
PI-033 - MULTISTATE MODEL TO INVESTIGATE OVERALL SURVIVAL (OS) FROM COPANLISIB PIVOTAL TRIALS.

Favorite
PI-034 - ONCOLOGIST CONSIDERATIONS WHEN CHOOSING BETWEEN 200 MG EVERY-3-WEEK VERSUS 400 MG EVERY-6-WEEK DOSING OF PEMBROLIZUMAB MONOTHERAPY WITHIN UPMC HILLMAN CANCER CENTER NETWORK

Favorite
PI-035 - PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED NEUROENDROCRINE PROSTATE CANCER (NEPC)

Favorite
PI-036 - POPULATION PHARMACOKINETIC MODELING OF SUNITINIB AND SU12662 IN PATIENTS WITH SOLID TUMORS

Favorite
PI-037 - QUANTITATIVE CLINICAL PHARMACOLOGY SUPPORTS TOTALITY OF EVIDENCE, DATA INTEGRATION AND DOSE SELECTION PROPOSAL OF A NEW MOLECULAR ENTITY WITH NO SINGLE AGENT ACTIVITY DEVELOPED IN COMBINATION: CASE STUDY OF ENGLUMAFUSP ALFA

Favorite
PI-038 - REVERSE-TRANSLATIONAL FINDINGS FOR DATOPOTAMAB DERUXTECAN (DATO-DXD) HUMAN EFFICACIOUS DOSE PREDICTION BASED ON MECHANISTIC PK/TUMOR GROWTH INHIBITION ANALYSIS FOR PATIENT-DERIVED AND CANCER CELL LINE-DERIVED XENOGRAFT MICE.

Favorite
PI-039 - TARGETING OF CDK12/13 AND ANDROGEN PATHWAYS IN MESTASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Favorite
PI-040 - THE EFFECT OF DORDAVIPRONE (ONC201) ON CARDIAC REPOLARIZATION IN HEALTHY ADULT PARTICIPANTS

Favorite
OAI-004 - GRIN2 IS A POWERFUL TOOL TO IDENTIFY GENOMIC HOT-SPOT LOCI AND ENABLES MULTI-OMICS INTEGRATION.

Favorite